Biogen (BIIB) said research and development, upfront payments and milestone charges are expected to reduce earnings by about $0.95 a share in Q2 and by $1.75 to $1.95 in Q3, reflecting potential milestones and transactions that haven't yet closed.
Results for the quarter ended June 30 have not been finalized, the company said Wednesday in a regulatory filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.